Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURIPANC: durvalumab + rintatolimod in metastatic pancreatic ductal adenocarcinoma
NL-OMON56232Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, rintatolimod in pancreatic adenocarcinoma (PDAC), pancreatic cancer (PC), sponsored by Erasmus MC. Started Jan 2024; status: recruiting.
02
Drugs
durvalumabrintatolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON56232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56232.